Kroll is excited to announce that Michael Kiely, President of U.S. Government Affairs at UPS and Jon Selib, Senior Vice President, Global Policy & Public Affairs at Pfizer will join Kroll's Chief Strategist Chris Campbell for a webcast to discuss the role of regulation in the life sciences industry. We hope you will join us!
Thursday, June 24, 2021
11:00 a.m. EDT/4:00 p.m. BST
This exciting event is part of a series of webinars, bringing together top experts and industry leaders to set the roadmap for a new era where pharma, patients, providers and society are united in their efforts of greater value. Please join us for our virtual Life Sciences Series held on June 22-24, 2021. Together, our leading experts and industry leaders will share insights on trends, valuation, technology, intellectual property (IP), risk and regulation to set the roadmap for a new era where pharma, patients, providers and society are united in their efforts of greater value.
Day 1: Tuesday, June 22 |
|
11:00 a.m. EST / 4:00 p.m. BST |
|
12:15 p.m. EST / 5:15 p.m. BST |
|
Day 2: Wednesday, June 23 |
|
11:00 a.m. EST / 4:00 p.m. BST |
|
Session 2 - Intellectual Property – Management, Protection and Enforcement |
12:15 p.m. EST / 5:15 p.m. BST |
Day 3: Thursday, June 24 |
|
11:00 a.m. EST / 4:00 p.m. BST |
|
12:15 p.m. EST / 5:15 p.m. BST |
Schedule: 11:00 a.m. EST / 4:00 p.m. BST
As big pharma and biotech conglomerates continue to seek growth following the COVID-19 pandemic, we will be joined by experts from within Duff & Phelps, A Kroll Business and the wider industry to who will look ahead to what will shape the future of the life sciences industry and dissect the key drivers of M&A activity.
Key Insights
Panelists
Schedule: 12:15 p.m. EST / 5:15 p.m. BST
Purchase accounting valuation in the biotechnology industry can be particularly challenging. Understanding the intricacies of biotechnology valuation and having command of best practices is key to successfully navigating the valuation process for all stakeholders. Duff & Phelps’ Life Sciences valuation advisory team will hold a webinar where we will walk you through a purchase price allocation for a hypothetical biotechnology company based on real-world experience.
Key Insights
Panelists
Schedule: 11:00 a.m. EST / 4:00 p.m. BST
Technology continues to impact the relationship between businesses and their stakeholders, with data exchange, digital service provision and innovation all driving discussion. Our panel of experts will address data-driven approaches to patient care, the impact of technology on regulation, and IP, data privacy and cyber security issues in the healthcare and life sciences industry.
Key Insights
Panelists
Schedule: 12:15 p.m. EST / 5:15 p.m. BST
Join our panel of leading attorneys for a discussion focused on current issues facing the life sciences industry with respect to the management, protection and enforcement of IP rights in the UK, Europe and the U.S.
Key Insights
Panelists
Schedule: 11:00 a.m. EST / 4:00 p.m. BST
Chris Campbell, Chief Strategist at Kroll, Michael Kiely, President of U.S. Government Affairs at UPS and Jon Selib, Senior Vice President, Global Policy & Public Affairs at Pfizer, will sit down for a fireside chat on the impact of regulation on the life sciences industry. They will discuss global regulations and emerging hot topics.
Key Insights
Panelists
Schedule: 12:15 p.m. EST / 5:15 p.m. BST
The discussion will provide insights on how the post-COVID-19 environment is challenging with the pharmaceutical and medical device industries. The increased public scrutiny and rapid development of and changes to these industries over the past year amplifies existing operational risks. Our panel of experts will address evolving risks challenging life sciences global-supply chain, identifying risk exposure and navigating the complex regulatory landscape.
Key Insights
Panelists
Valuation of businesses, assets and alternative investments for financial reporting, tax and other purposes.
Middle Market M&A, Strategic Advisory, Debt Advisory and Private Capital Markets, Restructuring and Insolvency Services, Financial Due Diligence, Fairness Opinions, Solvency Opinions and ESOP/ERISA Advisory.
The Kroll Investigations, Diligence and Compliance team partners with clients to anticipate, detect and manage regulatory and reputational risks associated with global ethics and compliance obligations.
The Kroll Investigations, Diligence and Compliance team are experts in forensic investigations and intelligence, delivering actionable data and insights that help clients worldwide make critical decisions and mitigate risk.
Seamless analytical advisory through the deal continuum, from transaction origination to closing.
Incident response, digital forensics, breach notification, managed detection services, penetration testing, cyber assessments and advisory.
Kroll’s Enterprise Security Risk Management practice provides expert guidance and advisory services to our global clientele as they navigate the most challenging and emerging security and threat-related issues.
End-to-end governance, advisory and monitorship solutions to detect, mitigate, drive efficiencies and remediate operational, legal, compliance and regulatory risk.
Independent expert analysis, testimony, advice and investigations for complex disputes and projects.